卵圆孔未闭与隐源性卒中的研究进展

doi:10.3969/j.issn.1673-5765.2019.05.010

摘要/Abstract

摘要：

隐源性卒中约占所有缺血性卒中的40%，其病因、诊断和治疗一直是临床工作者的研究热点。近年来发现，卵圆孔未闭与隐源性卒中的发病密切相关，是隐源性卒中的重要危险因素。在临床中常用经食管超声心动图、经胸壁超声心动图、经颅多普勒发泡试验和心脏MRI等方法来检测卵圆孔未闭。反常栓塞是卵圆孔未闭导致隐源性卒中的主要发病机制。在头部影像学检查中，绝大多数卵圆孔未闭相关隐源性卒中患者为多血管分布区的多发散在小梗死。在药物治疗方面，抗血小板药物相对于抗凝药物，可能更适合大多数卵圆孔未闭合并隐源性卒中的患者。此外，近期多项临床随机对照研究均表明，卵圆孔未闭封堵术对于预防卵圆孔未闭合并隐源性卒中患者卒中再发的疗效明显优于药物治疗。

文章导读： 本文从检查方法、发病机制、影像及治疗方面对卵圆孔未闭和隐源性卒中研究现状展开介绍。

关键词: 卵圆孔未闭; 隐源性卒中; 反常栓塞; 治疗

Abstract:

Cryptogenic stroke accounts for about 40% of all ischemic stroke. Its etiology, diagnosis and treatment have been the focus of clinical research. It has been found that patent foramen ovale (PFO) is closely related to cryptogenic stroke, and it is an important risk factor for cryptogenic stroke. PFO can be detected by transesophageal echocardiography, transthoracic echocardiography, transcranial Doppler foaming test and cardiac MRI. Paradoxical embolism is the main pathogenesis of occult stroke caused by PFO. The imaging features in most PFO-related cryptogenic stroke patients are multiple scattered small lesions in multiple vascular territories. Antiplatelet may be more suitable than anticoagulants therapy for most cryptogenic stroke patients with PFO. In addition, recent randomized controlled trials indicated that PFO closure was superior to drug therapy in preventing stroke recurrence in cryptogenic stroke patients with PFO.

Key words: Patent foramen ovale; Cryptogenic stroke; Paradoxical embolism; Treatment

陈竹林，黄光. 卵圆孔未闭与隐源性卒中的研究进展[J]. 中国卒中杂志, 2019, 14(05): 457-462.

CHEN Zhu-Lin, HUANG Guang. Progress in Patent Foramen Ovale and Cryptogenic Stroke[J]. Chinese Journal of Stroke, 2019, 14(05): 457-462.

参考文献

[1] FONSECA A C，FERRO J M. Cryptogenic stroke[J].

Eur J Neurol，2015，22（4）：618-623.

[2] BOUTET C，ROUFFIANGE-LECLAIR L，

GARNIER P，et al. Brain magnetic resonance

imaging findings in cryptogenic stroke patients

under 60 years with patent foramen ovale[J]. Eur J

Radiol，2014，83（5）：824-828.

[3] SAVINO K，MAIELLO M，PELLICCIA F，et a1.

Patent foramen ovale and cryptogenic stroke：from

studies to clinical practice：position paper of the

Italian Chapter International Society Cardiovascular

Ultrasound[J]. Int J Clin Pract，2016，70（8）：641-

648.

[4] NAKANISHI K，YOSHIYAMA M，HOMMA S.

Patent foramen ovale and cryptogenic stroke[J].

Trends Cardiovasc Med，2017，27（8）：575-581.

[5] CHU W，WANG H. Transesophageal

echocardiography in cardiogenic embolic cerebral

infarction[J]. Pak J Med Sci，2018，34（1）：58-61.

[6] GHAZAL S N. Valsalva maneuver in echocardiography[

J]. J Echocardiogr，2017，15（1）：1-5.

[7] NAJIB M Q，GANJI J L，CHALIKI H P.

Visualization of atrial septal aneurysm and patent

foramen ovale by three-dimensional transesophageal

echocardiography[J/OL]. J Cardiovasc Med

（Hagerstown），2016，17（2）：e237-e238. https：//doi.

org/10.2459/JCM.0000000000000164.

[8] JUSUFOVIC M，THOMASSEN L，SKJELLAND M，

et al. Ischaemic stroke with patent foramen ovale[J].

Tidsskr Nor Laegeforen，2014，134（2）：180-184.

[9] FENG C，LUO T，LUO Y，et al. Contrastenhanced

transthoracic echocardiography applied

in evaluation of pulmonary right-to-left shunt：a

preliminary study[J/OL]. Comput Med Imaging

Graph，2018，68：55-60. https：//doi.org/10.1016/

j.compmedimag.2018.04.007.

[10] MURATORI M，ITALIANO G，INNOCENTI E，et

al. P594 Contrast transthoracic echocardiography as

a gatekeeper for patent foramen ovale closure[J]. Eur

Heart J Cardiovasc Imaging，2016，17（2）：109-113.

[11] LI X，GAO Y H，WU S Z，et al. Contrast

transthoracic echocardiography using 50% glucose

as a contrast agent for screening of a patent foramen

ovale[J]. Ultrasound Med Biol，2018，44（11）：2267-

2273.

[12] BANG O Y，LEE M J，RYOO S，et al. Patent

foramen ovale and stroke-current status[J]. J Stroke，

2015，17（3）：229-237.

[13] MOJADIDI M K，ZHANG L，CHUGH Y，et al.

Transcranial Doppler：does addition of blood to

agitated saline affect sensitivity for detecting cardiac

right-to-left shunt?[J]. Echocardiography，2016，33

（8）：1219-1227.

[14] MAHMOUD A N，ELGENDY I Y，AGARWAL

N，et al. Identification and quantification of patent

foramen ovale-mediated shunts：echocardiography

and transcranial Doppler[J]. Interv Cardiol Clin，

2017，6（4）：495-504.

[15] D'ANDREA A，CONTE M，RIEGLER L，et

al. Transcranial Doppler ultrasound：incremental

diagnostic role in cryptogenic stroke Part Ⅱ[J]. J

Cardiovasc Echogr，2016，26（3）：71-77.

[16] NALSU J，TAINA M，MUSTONEN P，et al. Soluble urokinase-type plasminogen activator receptor

predicts all-cause5-year mortality in ischemic stroke

and TIA[J]. In Vivo，2017，31（3）：381-386.

[17] HAMILTON-CRAIG C，SESTITO A，NATALE L，

et al. Contrast echocardiography remains superior

to contrast-enhanced cardiac magnetic resonance

imaging for the diagnosis of patent foramen ovale[J].

Eur J Echocardiogr，2011，12（3）：222-227.

[18] STORTECKY S，DA COSTA B R，MATTLE H P，et

al. Percutaneous closure of patent foramen ovale in

patients with cryptogenic embolism：a network metaanalysis[

J]. Eur Heart J，2015，36（2）：120-128.

[19] OSGOOD M，BUDMAN E，CARANDANG R，et

al. Prevalence of pelvic vein pathology in patients

with cryptogenic stroke and patent foramen ovale

undergoing MRV pelvi[J]. Cerebrovasc Dis，2015，39

（3-4）：216-223.

[20] AMIN H，GREER D M. Cryptogenic stroke-the

appropriate diagnostic evaluation[J]. Curr Treat

Options Cardiovasc Med，2014，16（1）：280.

[21] KENT D M，RUTHAZER R，WEIMAR C，et al. An

index to identify stroke-related vs incidental patent

foramen ovale in cryptogenic stroke[J]. Neurology，

2013，81（7）：619-625.

[22] MARIUCCI E，DONTI A，SALOMONE L，et al.

Recurrent stroke after transcatheter PFO closure in

cryptogenic stroke or TIA：long-term follow-up[J/

OL]. Cardiol Res Pract，2017：9849425. https：//doi.

org/10.1155/2017/9849425.

[23] SATTIRAJU S，MASRI S C，LIAO K，et al. Threedimensional

transesophageal echocardiography of a

thrombus entrapped by apatent foramen ovale[J/OL].

Ann Thorac Surg，2012，94（4）：e101-e102. https：//

doi.org/10.1016/j.athoracsur.2012.04.129.

[24] KJELD T，JØRGENSEN T S，FORNITZ G，et al.

Patent foramen ovale and atrial fibrillation as causes

of cryptogenic stroke：is treatment with surgery

superior to device closure and anticoagulation? A

review of the literature[J]. Acta Radiol Open，2018，7

（9）：1-10.

[25] RYOO S，CHUNG J W，LEE M J，et a1. An

approach to working up cases of embolic stoke

of undetermined source[J/OL]. J Am Heart Assoc，

2016，5（3）：e002975. https：//doi.org/10.1161/

JAHA.115.002975.

[26] KIM B J，SOHN H，SUN B J，et al. Imaging

characteristics of ischemic strokes related to patent

foramen ovale[J]. Stroke，2013，44（12）：3350-3356.

[27] MAS J L，DERUMEAUX G，GUILLON B，et al.

Patent foramen ovale closure or anticoagulation vs.

antiplatelets after stroke[J]. N Engl J Med，2017，377

（11）：1011-1021.

[28] SHARIAT A，YAGHOUBI E，FARAZDAGHI

M，et a1. Comparison of medical treatments in

cryptogenic stroke patients with patent foramen

ovale：a randomized clinical trial[J]. J Res Med Sci，

2013，18（2）：94-98.

[29] KENT D M，DAHABREH I J，RUTHAZER R，et

a1. Anticoagulant vs. antiplatelet therapy in patients

with cryptogenic stroke and patent foramen ovale：

an individual participant data meta-analysis[J]. Eur

Heart J，2015，36（35）：2381-2389.

[30] KERNAN W N，OVBIAGELE B，KITTNER S J.

Response to letter regarding article，" Guidelines for

the prevention of stroke in patients with stroke and

transient ischemic attack：a guideline for healthcare

professionals from the American Heart Association

/American Stroke Association"[J/OL]. Stroke，

2015，46（4）：e87-e89. https：//doi.org/10.1161/

STROKEAHA.115.008661.

[31] MEIER B，KALESAN B，MATTLE H P，et al.

Percutaneous closure of patent foramen ovale in

cryptogenic embolism[J]. N Engl J Med，2013，368

（12）：1083-1091.

[32] CARROLL J D，SAVER J L，THALER D E，et

al. Closure of patent foramen ovale versus medical

therapy after cryptogenic stroke[J]. N Engl J Med，

2013，368（12）：1092-1100.

[33] MAS J L，DERUMEAUX G，GUILLON B，et al.

Patent foramen ovale closure or anticoagulation vs.

antiplatelets after stroke[J]. N Engl J Med，2017，377

（11）：1011-1021.

[34] SAVER J L，CARROLL J D，THALER D E，et al.

Long-term outcomes of patent foramen ovale closure

or medical therapy after stroke[J]. N Engl J Med，

2017，377（11）：1022-1032.

[35] SONDERGAARD L，KASNER S E，RHODES J

F，et al. Patent foramen ovale closure or antiplatelet

therapy for cryptogenic stroke[J]. N Engl J Med，

2017，377（11）：1033-1042.

[36] AHMAD Y，HOWARD J P，ARNOLD A，et

al. Patent foramen ovale closure vs. medical

therapy forcryptogenic stroke：a meta-analysis of

randomized controlled trials[J]. Eur Heart J，2018，

39（18）：1638-1649.